Cancer Stem Cell News 7.22 June 6, 2018 | |
| |
TOP STORYFor patients with chronic lymphocytic leukemia (CLL), self-renewing, neoplastic B cells express ROR1 in 95% of cases. High-level leukemia cell expression of ROR1 is associated with an unfavorable prognosis. Scientists conducted a Phase I study involving 26 patients with progressive, relapsed, or refractory CLL. [Cell Stem Cell] Abstract | Press Release 1 | Press Release 2 | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Cigarette Smoke Induces Stem Cell Features of Pancreatic Cancer Cells via PAF1 Chronic exposure of HPNE and Capan1 cells to cigarette smoke extract caused them to increase markers of stem cells, including autofluorescence and sphere formation, compared to control cells. [Gastroenterology] Abstract Ibrutinib Inactivates BMX-STAT3 in Glioma Stem Cells to Impair Malignant Growth and Radioresistance Researchers demonstrated that bone marrow and X-linked (BMX) inhibition by ibrutinib potently disrupts glioblastoma (GBM) harbors glioma stem cells (GSCs), suppresses GBM malignant growth, and effectively combines with radiotherapy. Ibrutinib markedly disrupted the BMX-mediated STAT3 activation in GSCs but showed minimal effect on neural progenitor cells lacking BMX expression. [Sci Transl Med] Abstract The transcriptome profile of ubiquitin-specific-peptidase 22 (USP22)-deficient KrasG12D/+ progenitors resembled leukemic stem cells and was highly correlated with genes associated with poor prognosis in acute myeloid leukemia. [Blood] Abstract Simvastatin Interferes with Cancer ‘Stem-Cell’ Plasticity Reducing Metastasis in Ovarian Cancer The authors studied whether simvastatin, a lipophilic statin, could impair the metastatic potential of cancer-initiating cells in high-grade serous ovarian cancer, the most lethal among the gynecologic malignancies. [Endocr Relat Cancer] Abstract Investigators report that luteolin suppresses prostate cancer (PCa) stemness through Wnt signaling by upregulation of frizzled class receptor 6 (FZD6). Luteolin inhibited PCa cell proliferation, migration, self-renewal as well as the expression of prostate cancer stem cell markers in vitro. [Sci Rep] Full Article Researchers demonstrated that miR-195-5p inhibited the stem-like capacity of colorectal cancer cells. They established 5-FU-resistant SW620 and HT-29 cell lines and performed a variety of functional assays following exposure to miR-195-5p and anti-miR-195-5p. [Int J Biol Macromol] Abstract To explore the characteristics of hepatic CSCs, investigators successfully enriched hepatic cancer stem-like cells from three established liver cancer cell lines. [BMC Cancer] Full Article Investigators delved into the molecular mechanisms underlying the M2-mediated cell proliferation arrest. Exploiting U87MG and U251MG cell lines as model systems, they evaluated the ability of M2 receptors to interfere with Notch-1 and EGFR pathways, whose activation promotes glioblastoma proliferation. [Int J Mol Sci] Full Article CD44 and aldehyde dehydrogenase 1 (ALDH1) has been reputed to be CSC markers in breast cancer. Scientists investigated the expression of these markers and their relation with conventional clinicopathologic tumor characteristic including molecular subtype. [Breast Cancer] Abstract | |
| |
REVIEWSDeubiquitinating Enzymes in Cancer Stem Cells: Functions and Targeted Inhibition for Cancer Therapy Researchers discuss the roles of various deubiquitination enzymes involved in the regulation of core stem cell transcription factors and CSC-related proteins that are implicated in the modulation of cellular processes and carcinogenesis. [Drug Discov Today] Abstract Prostate Cancer Stem Cells: Current Understanding The authors discuss the current methods for prostate cancer stem cell (PCSC) enrichment and analysis, the hallmarks of PCSC metabolism and the role of PCSCs in tumor progression. [Stem Cells] Abstract Visit our reviews page to see a complete list of reviews in the cancer stem cell research field. | |
| |
INDUSTRY NEWSExelixis, Inc. announced an amendment to the protocol for COSMIC-021, the Phase Ib trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors to add 10 new expansion cohorts to the trial. [Exelixis, Inc.] Press Release UT Health San Antonio Receives $24 Million NIH Research Boost UT Health San Antonio will receive $24 million over the next five years under the Clinical and Translational Science Award (CTSA) Program. The university is a CTSA Program hub and collaborates with eight regional partners. [The University of Texas Health Science Center at San Antonio] Press Release Evotec Forms Academic BRIDGE LAB591 with Arix Bioscience and Fred Hutchinson Cancer Research Center Evotec AG announced the formation of the LAB591 academic BRIDGE with Arix Bioscience plc and the Fred Hutchinson Cancer Research Center. LAB591 aims to accelerate research discoveries at Fred Hutch and leverage these discoveries to form new companies focused on cancer and infectious disease drug development. [Evotec AG] Press Release | |
| |
POLICY NEWSScientists Fare Poorly in Super Tuesday Primary Vote Science-minded candidates seeking seats in the next U.S. Congress took a drubbing from their Democratic opponents in a raft of primary elections across the country. [ScienceInsider] Editorial Chile, Keen to Become a Knowledge Society, Creates a Ministry of Science Scientists in Chile have welcomed a decision by Congress to create a science ministry. Many researchers hope that a dedicated ministry will give science more prominence and better-coordinated policies—provided the ministry’s budget matches the government’s ambitions to “bring Chile towards an information and knowledge society,” as Gonzalo Blumel, the country’s minister secretary-general of the presidency, put it in a statement issued after the 31 May vote. [ScienceInsider] Editorial Europe’s Top Science Funder Shows High-Risk Research Pays Off A popular and unusual self-review carried out by Europe’s most prestigious science funder is back. The annual assessment, now in its third year, found that nearly one in five projects by the European Research Council led to a scientific breakthrough. [Nature News] Editorial
| |
EVENTSNEW The American Society for Cell Biology (ASCB) Annual Meeting 2018 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Tenure-Track Faculty Positions – Various (The Ohio State University) PhD Student – Cell Signaling (German Cancer Research Center) Postdoctoral Position – Stem Cell Bioinformatics (University of Copenhagen) Postdoctoral Fellow – Glioma Epigenetics and Signaling (NYU School of Medicine) Postdoctoral Position – Cancer Research (Institute for Research in Biomedicine) Postdoctoral Research Fellow – Cancer Stem Cells (University of New South Wales) Professor – Cancer Stem Cell Research (Cardiff University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|